Merck Strategy Still Murky As Jury Mulls Vioxx Claims

Law360, New York (July 12, 2006, 12:00 AM EDT) -- For Merck & Co. to successfully defend itself against more than 13,000 lawsuits over the former blockbuster drug Vioxx, the case deliberated Wednesday by a New Jersey jury seems like a must-win.

The plaintiff in the lawsuit, Elaine Doherty, is blaming Vioxx for a heart attack she suffered in January 2004 after taking the drug for arthritis for 2 1/2 years.

Yet the 68-year-old homemaker also suffered from severely clogged arteries, obesity, high blood pressure, a cholesterol problem, a family history of heart disease and an...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.